Liat Hayardeny

1.8k total citations
35 papers, 1.2k citations indexed

About

Liat Hayardeny is a scholar working on Immunology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Liat Hayardeny has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 14 papers in Pathology and Forensic Medicine and 9 papers in Molecular Biology. Recurrent topics in Liat Hayardeny's work include Multiple Sclerosis Research Studies (14 papers), Neuroinflammation and Neurodegeneration Mechanisms (8 papers) and Toxin Mechanisms and Immunotoxins (8 papers). Liat Hayardeny is often cited by papers focused on Multiple Sclerosis Research Studies (14 papers), Neuroinflammation and Neurodegeneration Mechanisms (8 papers) and Toxin Mechanisms and Immunotoxins (8 papers). Liat Hayardeny collaborates with scholars based in Israel, Germany and United States. Liat Hayardeny's co-authors include Wolfgang Brück, Christiane Wegner, Christine Stadelmann, Ralf Gold, Michael R. Hayden, Gıancarlo Comı, Gisa Ellrichmann, Uwe‐Karsten Hanisch, Ralf A. Linker and Gareth John and has published in prestigious journals such as Neurology, Scientific Reports and Journal of Neurochemistry.

In The Last Decade

Liat Hayardeny

34 papers receiving 1.1k citations

Peers

Countries citing papers authored by Liat Hayardeny

Since Specialization

Citations

This map shows the geographic impact of Liat Hayardeny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liat Hayardeny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liat Hayardeny more than expected).

Fields of papers citing papers by Liat Hayardeny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liat Hayardeny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liat Hayardeny. The network helps show where Liat Hayardeny may publish in the future.

Co-authorship network of co-authors of Liat Hayardeny

This figure shows the co-authorship network connecting the top 25 collaborators of Liat Hayardeny. A scholar is included among the top collaborators of Liat Hayardeny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liat Hayardeny. Liat Hayardeny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis 2021 ·JHEP Reports ·Dipankar Bhattacharya, (unknown), José M. Mato, Amanda J. Craig, David Fernández‐Ramos, Fernando Lopitz‐Otsoa, (unknown), Liat Hayardeny, Vasuretha Chandar, Robert E. Schwartz, Augusto Villanueva, Scott L. Friedman	60
2	Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation 2020 ·World Journal of Gastroenterology ·David Fernández‐Ramos, Fernando Lopitz‐Otsoa, Laura delaCruz‐Villar, (unknown), Martina Pagano, Laura Mosca, Maider Bizkarguenaga, Marina Serrano‐Maciá, Mikel Azkargorta, Marta Iruarrizaga‐Lejarreta, Jesús Sot, (unknown), (unknown), Félix M. Goñi, Cristina Alonso, Maria Luz Martínez‐Chantar, Félix Elortza, Liat Hayardeny, Shelly C. Lu, José M. Mato	27
3	Laquinimod enhances central nervous system barrier functions 2017 ·Neurobiology of Disease ·Fred Lühder, Hania Kébir, Francesca Odoardi, (unknown), (unknown), Jorge I. Alvarez, Jan Winchenbach, (unknown), Liat Hayardeny, Ella Sorani, Dmitri Lodygin, Alexander Flügel, Alexandre Prat	15
4	Laquinimod treatment in the R6/2 mouse model 2017 ·Scientific Reports ·Gisa Ellrichmann, (unknown), (unknown), (unknown), Christiane Reick, Liat Hayardeny, Michael R. Hayden, (unknown), Konstanze F. Winklhofer, Carsten Saft, Ralf Gold	42
5	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS 2017 ·Journal of Neuroinflammation ·Tjalf Ziemssen, Hayrettin Tumani, (unknown), Katja Thomas, Friedemann Paul, Nils Richter, Emil Samara, Ofer Spiegelstein, Ella Sorani, (unknown), (unknown), Liat Hayardeny	15
6	Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease 2017 ·Journal of Neuroimmunology ·Rehana Z. Hussain, William A. Miller-Little, Doris Lambracht‐Washington, (unknown), Masaya Takahashi, Shanrong Zhang, Min Fu, Gary Cutter, Liat Hayardeny, Craig M. Powell, Roger N. Rosenberg, Olaf Stüve	5
7	Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease 2016 ·Scientific Reports ·Marta Garcia‐Miralles, Xin Hong, Liang Tan, Nicholas S. Caron, Yihui Huang, Xuan Vinh To, (unknown), Sonia Franciosi, Spyros Papapetropoulos, Liat Hayardeny, Michael R. Hayden, Kai‐Hsiang Chuang, Mahmoud A. Pouladi	56
8	Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research 2016 ·Progress in Neurobiology ·Iris Grossman, Volker Knappertz, Daphna Laifenfeld, Colin J.D. Ross, (unknown), Sarah Kolitz, David Ladkani, Liat Hayardeny, Pippa S. Loupe, Ralph Laufer, Michael R. Hayden	20
9	The role of laquinimod in modulation of the immune response in relapsing–remitting multiple sclerosis: Lessons from gene expression signatures 2015 ·Journal of Neuroimmunology ·Rina Zilkha‐Falb, Michael Gurevich, Liat Hayardeny, Anat Achiron	8
10	Laquinimod suppresses CNS autoimmunity by activation of natural killer cells (P1.161) 2015 ·Neurology ·Stefan Nessler, Martina Ott, Christiane Wegner, Liat Hayardeny, Evelyn Ullrich, Wolfgang Brück	1
11	Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids 2015 ·Scientific Reports ·Sarah Kolitz, (unknown), Fadi Towfic, Jason Funt, (unknown), Kevin Fowler, Daphna Laifenfeld, (unknown), Maxim N. Artyomov, Tal Birnberg, (unknown), (unknown), Liat Hayardeny, David Ladkani, Michael R. Hayden, Benjamin Zeskind, Iris Grossman	15
12	Immune surveillance of the central nervous system in multiple sclerosis — Relevance for therapy and experimental models 2014 ·Journal of Neuroimmunology ·Rehana Z. Hussain, Liat Hayardeny, (unknown), Felix Yarovinsky, Todd N. Eagar, (unknown), (unknown), (unknown), Olaf Stüve	24
13	Glatiramer Acetate Protects Against Inflammatory Synaptopathy in Experimental Autoimmune Encephalomyelitis 2013 ·Journal of Neuroimmune Pharmacology ·Antonietta Gentile, Silvia Rossi, Valeria Studer, Caterina Motta, Valentina De Chiara, Alessandra Musella, Helena Sepman, Diego Fresegna, Gabriele Musumeci, Giorgio Grasselli, Nabila Haji, (unknown), Liat Hayardeny, Georgia Mandolesi, Diego Centonze	21
14	Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod 2013 ·Journal of Neuroimmunology ·Brett T. Lund, Eve E. Kelland, Liat Hayardeny, (unknown), Wendy Gilmore, Leslie P. Weiner	15
15	Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis 2012 ·Journal of Neuroimmunology ·Elias Toubi, (unknown), Elsebeth Staun-Ram, Ayelet Snir, Doron Melamed, Liat Hayardeny, Ariel Miller	48
16	Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis 2012 ·Journal of Neuroimmunology ·Rina Aharoni, (unknown), Raya Eilam, Liat Hayardeny, Michael Sela, Ruth Arnon	59
17	Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination 2012 ·Acta Neuropathologica ·Wolfgang Brück, (unknown), Trinh Pham, Jingya Zhang, Liat Hayardeny, (unknown), Uwe‐Karsten Hanisch, Tommy Regen, Denise van Rossum, (unknown), (unknown), Tanja Kuhlmann, Christine Stadelmann, Gareth John, (unknown), Christiane Wegner	144
18	Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor 2011 ·American Journal Of Pathology ·Jan Thöne, Gisa Ellrichmann, Silvia Seubert, (unknown), (unknown), Rebecca Conrad, Liat Hayardeny, Gıancarlo Comı, Stefan Wiese, Ralf A. Linker, Ralf Gold	115
19	Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: Role of IGF-2 2010 ·Journal of Neuroimmunology ·(unknown), (unknown), Nadia Ouamara, Andleeb Zameer, Gregory Cosentino, Michael Mayne, Liat Hayardeny, Jack P. Antel, Amit Bar‐Or, Gareth John	25
20	Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis 2010 ·Journal of Neuroimmunology ·Christiane Wegner, Christine Stadelmann, (unknown), (unknown), Sara W. Feigelson, R. Alon, (unknown), Liat Hayardeny, Wolfgang Brück	106

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact